Boundless Bio（BOLD）株式概要バウンドレス・バイオ社は、癌遺伝子増幅癌患者の治療のために染色体外DNA（ecDNA）を標的とした治療法を開発する臨床段階の癌治療企業である。 詳細BOLD ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性6/6配当金0/6リスク分析収益が 100 万ドル未満 ( $0 )今後3年間の収益は年平均6.9%減少すると予測されている。 意味のある時価総額がありません ( $33M )現在は利益が出ておらず、今後3年間で利益が出る見込みはない すべてのリスクチェックを見るBOLD Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$1.49該当なし内在価値ディスカウントEst. Revenue$PastFuture-66m12016201920222025202620282031Revenue US$1.0Earnings US$0.2AdvancedSet Fair ValueView all narrativesBoundless Bio, Inc. 競合他社EvaxionSymbol: NasdaqCM:EVAXMarket cap: US$32.7mNanoViricidesSymbol: NYSEAM:NNVCMarket cap: US$32.0mCervoMedSymbol: NasdaqCM:CRVOMarket cap: US$31.8mNextCureSymbol: NasdaqGS:NXTCMarket cap: US$35.1m価格と性能株価の高値、安値、推移の概要Boundless Bio過去の株価現在の株価US$1.4952週高値US$1.7252週安値US$0.96ベータ0.951ヶ月の変化-5.70%3ヶ月変化29.57%1年変化-11.83%3年間の変化n/a5年間の変化n/aIPOからの変化-89.54%最新ニュースお知らせ • Apr 30Boundless Bio, Inc., Annual General Meeting, Jun 15, 2026Boundless Bio, Inc., Annual General Meeting, Jun 15, 2026.お知らせ • Apr 18Boundless Bio Presents Preclinical Data Supporting Ongoing Clinical Development of BBI-940Boundless Bio presented preclinical data supporting its lead ecDNA-directed therapy (ecDTx), BBI-940, at the American Association for Cancer Research Annual Meeting 2026. Boundless has identified a novel kinesin target (“Kinesin”) essential to ecDNA segregation and inheritance in cancer cells, but non-essential in healthy cells. BBI-940, an oral, and selective Kinesin degrader, is currently being evaluated in the Phase 1 KOMODO-1 trial in patients with advanced or metastatic ER+/HER2- breast cancer and TNBC-LAR. Genetic and pharmacologic degradation of Kinesin caused ecDNA mis-segregation, ecDNA depletion, and reduced viability of ecDNA+ cancer cells. Selective degradation of Kinesin in a panel of tumor cell lines demonstrated sensitivity across multiple tumor types and 32% sensitivity in breast cancer cell lines, including those positive for ecDNA and FGFR1 gain. This molecularly defined subgroup for Kinesin degradation was further validated in vivo with demonstrated monotherapy tumor regressions in an ecDNA+ TNBC-LAR model, and significant antitumor activity as monotherapy and combination in an ecDNA+/FGFR1+ ER+ breast cancer model. BBI-940 targets a specific kinesin protein, “Kinesin”, essential for ecDNA segregation and inheritance in cancer cells, but non-essential in healthy cells. BBI-940 is designed to exploit the heightened dependence of ecDNA-positive tumors on mitotic machinery by degrading Kinesin to induce mitotic catastrophe and cell death.New Risk • Mar 09New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 6.7% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 6.7% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$74m net loss in 3 years). Market cap is less than US$100m (US$25.3m market cap).Price Target Changed • Feb 11Price target increased by 33% to US$4.00Up from US$3.00, the current price target is provided by 1 analyst. New target price is 260% above last closing price of US$1.11. Stock is down 50% over the past year. The company is forecast to post a net loss per share of US$2.48 next year compared to a net loss per share of US$3.85 last year.分析記事 • Feb 04Is Boundless Bio (NASDAQ:BOLD) In A Good Position To Invest In Growth?Just because a business does not make any money, does not mean that the stock will go down. For example, although...お知らせ • Jan 20Boundless Bio, Inc. Advances Novel Kinesin Degrader Program BBI-940Boundless Bio, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for its novel Kinesin oral degrader program, BBI-940. The Company also provided updates on the POTENTIATE clinical trial of BBI-355 and BBI-825 and its capital position. The acceptance of the BBI-940 IND enables Boundless to advance the program into a first-in-human clinical trial for patients with metastatic breast cancer, KOMODO-1 (Kinesin Oral Molecular Degrader for Oncology-1), which is expected to initiate in the first half of 2026. Boundless's novel Kinesin oral de grader program targets a previously undrugged kinesin involved in DNA segregation, including ecDNA segregation, during mitosis. Following a strategic portfolio review, Boundless Bio has elected to cease enrollment of the Phase 1/2 POTENTIATE trial evaluating the combination of BBI-355, its oral, selective CHK1 inhibitor and BBI-825, its oral, selective RNR inhibitor, in oncogene-amplified cancers. This decision reflects market considerations, clinical data, and the Company's prioritization of programs with the greatest potential to deliver meaningful clinical impact and long-term value.最新情報をもっと見るRecent updatesお知らせ • Apr 30Boundless Bio, Inc., Annual General Meeting, Jun 15, 2026Boundless Bio, Inc., Annual General Meeting, Jun 15, 2026.お知らせ • Apr 18Boundless Bio Presents Preclinical Data Supporting Ongoing Clinical Development of BBI-940Boundless Bio presented preclinical data supporting its lead ecDNA-directed therapy (ecDTx), BBI-940, at the American Association for Cancer Research Annual Meeting 2026. Boundless has identified a novel kinesin target (“Kinesin”) essential to ecDNA segregation and inheritance in cancer cells, but non-essential in healthy cells. BBI-940, an oral, and selective Kinesin degrader, is currently being evaluated in the Phase 1 KOMODO-1 trial in patients with advanced or metastatic ER+/HER2- breast cancer and TNBC-LAR. Genetic and pharmacologic degradation of Kinesin caused ecDNA mis-segregation, ecDNA depletion, and reduced viability of ecDNA+ cancer cells. Selective degradation of Kinesin in a panel of tumor cell lines demonstrated sensitivity across multiple tumor types and 32% sensitivity in breast cancer cell lines, including those positive for ecDNA and FGFR1 gain. This molecularly defined subgroup for Kinesin degradation was further validated in vivo with demonstrated monotherapy tumor regressions in an ecDNA+ TNBC-LAR model, and significant antitumor activity as monotherapy and combination in an ecDNA+/FGFR1+ ER+ breast cancer model. BBI-940 targets a specific kinesin protein, “Kinesin”, essential for ecDNA segregation and inheritance in cancer cells, but non-essential in healthy cells. BBI-940 is designed to exploit the heightened dependence of ecDNA-positive tumors on mitotic machinery by degrading Kinesin to induce mitotic catastrophe and cell death.New Risk • Mar 09New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 6.7% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 6.7% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$74m net loss in 3 years). Market cap is less than US$100m (US$25.3m market cap).Price Target Changed • Feb 11Price target increased by 33% to US$4.00Up from US$3.00, the current price target is provided by 1 analyst. New target price is 260% above last closing price of US$1.11. Stock is down 50% over the past year. The company is forecast to post a net loss per share of US$2.48 next year compared to a net loss per share of US$3.85 last year.分析記事 • Feb 04Is Boundless Bio (NASDAQ:BOLD) In A Good Position To Invest In Growth?Just because a business does not make any money, does not mean that the stock will go down. For example, although...お知らせ • Jan 20Boundless Bio, Inc. Advances Novel Kinesin Degrader Program BBI-940Boundless Bio, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for its novel Kinesin oral degrader program, BBI-940. The Company also provided updates on the POTENTIATE clinical trial of BBI-355 and BBI-825 and its capital position. The acceptance of the BBI-940 IND enables Boundless to advance the program into a first-in-human clinical trial for patients with metastatic breast cancer, KOMODO-1 (Kinesin Oral Molecular Degrader for Oncology-1), which is expected to initiate in the first half of 2026. Boundless's novel Kinesin oral de grader program targets a previously undrugged kinesin involved in DNA segregation, including ecDNA segregation, during mitosis. Following a strategic portfolio review, Boundless Bio has elected to cease enrollment of the Phase 1/2 POTENTIATE trial evaluating the combination of BBI-355, its oral, selective CHK1 inhibitor and BBI-825, its oral, selective RNR inhibitor, in oncogene-amplified cancers. This decision reflects market considerations, clinical data, and the Company's prioritization of programs with the greatest potential to deliver meaningful clinical impact and long-term value.分析記事 • Oct 17Here's Why We're Watching Boundless Bio's (NASDAQ:BOLD) Cash Burn SituationEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Price Target Changed • Aug 24Price target decreased by 13% to US$3.50Down from US$4.00, the current price target is an average from 2 analysts. New target price is 199% above last closing price of US$1.17. Stock is down 69% over the past year. The company is forecast to post a net loss per share of US$2.46 next year compared to a net loss per share of US$3.85 last year.お知らせ • Jun 30+ 16 more updatesBoundless Bio, Inc.(NasdaqGS:BOLD) dropped from Russell 2000 Growth IndexBoundless Bio, Inc.(NasdaqGS:BOLD) dropped from Russell 2000 Growth Indexお知らせ • May 26+ 1 more updateBoundless Bio, Inc. Announces Workforce Reduction of Approximately One-Third of the Company’s WorkforceOn May 23, 2025, Boundless Bio, Inc. announced a workforce reduction of approximately one-third of the Company’s workforce. The Company expects to incur one-time costs of approximately $1.2 million in connection with the workforce reduction primarily related to one-time termination benefits (some of which are contractual), including severance and healthcare related benefits. The Company estimates that the workforce reduction will be substantially completed in the second quarter of 2025 and that the majority of the related charges will be recognized in the Company’s second quarter financial results of operations. The estimate of costs that the Company expects to incur and the timing thereof are subject to a number of assumptions, and actual results may differ materially. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the implementation of the workforce reduction.お知らせ • Apr 30Boundless Bio, Inc., Annual General Meeting, Jun 23, 2025Boundless Bio, Inc., Annual General Meeting, Jun 23, 2025.New Risk • Apr 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 18% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$94m net loss in 2 years). Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (US$32.3m market cap).お知らせ • Feb 03Boundless Bio Appoints Robert Doebele, M.D., Ph.D., as Chief Medical OfficerBoundless Bio, Inc. announced that Robert (“Bob”) Doebele, M.D., Ph.D., has been appointed as Chief Medical Officer. Dr. Doebele was the co-founder of Rain Oncology, Inc., (acquired by Pathos AI), a precision oncology company, where he served as Chief Scientific and Medical Officer, directing the research and development of innovative therapies targeting oncogenic drivers in tumor-agnostic, biomarker-driven trials. Specifically, he led the clinical development plans for milademetan, a small molecule MDM2 inhibitor, Phase 2 planning for tarloxotinib, a hypoxia-activated pan-HER kinase inhibitor, and the development of a preclinical program focused on inducing synthetic lethality by inhibiting RAD52. Dr. Doebele previously led the research and clinical trials at the University of Colorado that launched the TRK inhibitor field by demonstrating that NTRK1/2/3 gene fusions represent a novel tumor agnostic target in cancer, a strategy that ultimately led to the approval of Vitrakvi® (larotrectinib) and Rozlytrek® (entrectinib). He also served as the director of the Thoracic Oncology Research Initiative at the University of Colorado Cancer Center and co-founded and co-directed the University of Colorado Molecular Tumor Board. Dr. Doebele received his M.D. and Ph.D. in Immunology from the University of Pennsylvania School of Medicine and an A.B. in Molecular Biology from Princeton University.分析記事 • Jan 13Here's Why We're Watching Boundless Bio's (NASDAQ:BOLD) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, although...お知らせ • Dec 13+ 1 more updateBoundless Bio, Inc. Changes to Management TeamBoundless Bio, Inc. announced that Klaus Wagner, M.D., Ph.D., Chief Medical Officer (CMO), and Neil Abdollahian, Chief Business Officer (CBO), will depart the company at the end of December and in early January 2025, respectively. James L. Freddo, M.D., current advisor to Boundless with nearly 30 years of clinical leadership experience in biopharmaceutical companies, will serve as Interim CMO while the company conducts a search for a permanent hire. Dr. Freddo’s extensive background includes serving as CMO and later as a member of the board of directors at Ignyta, Inc., CMO and Senior Vice President, Development at Anadys Pharmaceuticals, and Vice President, Clinical Development, Oncology at Pfizer. The company does not intend to appoint a new CBO at this time.お知らせ • Oct 14Boundless Bio Announces Departure of Jami Rubin as Chief Financial OfficerBoundless Bio announced that Jami Rubin has stepped down from her role as Chief Financial Officer (CFO) for personal reasons. Boundless Bio does not plan to hire a successor CFO at this time; David Hinkle, Senior Vice President, Finance and Controller, will maintain responsibility for the company’s Finance operations and assume the roles of principal financial and accounting officer.分析記事 • Sep 27Will Boundless Bio (NASDAQ:BOLD) Spend Its Cash Wisely?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...お知らせ • Aug 13Boundless Bio Provides Business Updates Focused on Key Value DriversBoundless Bio, Inc. provided business updates for the company's top strategic priorities. In alignment with its strategic priorities, Boundless Bio has narrowed its discovery research work and, as a result, modestly reduced its workforce. BBI-355, a novel, oral, potent, selective CHK1 inhibitor targeting replication stress for cancer patients with driver oncogene amplifications. The company presented preclinical and clinical pharmacodynamic data on BBI-355 at the American Association for Cancer Research (AACR) Annual Meeting in April 2024. Enrollment is progressing in the Phase 1/2 POTENTIATE clinical trial evaluating BBI-355 as a single agent and in combination with targeted therapies in patients with locally advanced or metastatic solid tumors with oncogene amplifications. BBI-825, a novel, oral, powerful RNR inhibitor targeting ecDNA assembly and repair for cancer patients with resistance oncogene amplifications. In April 2024, the company announced the first patient had been dosed with BBI-825 in the Phase 1/2 STARMAP clinical trial. ECTA was previously determined by the FDA to be a non-significant risk device for use as a clinical trial assay (CTA) in the BBI-355 POTENTIATE trial. About BBI-355: BBI-355, is a novel, oral, selective small molecule inhibitor of checkpoint kinase 1 (CHK1) being studied in the ongoing, first-in-human, Phase 1/2 POTentIATE clinical trial (NCT05827614) in cancer patients with oncogene amplifications; BBI-825, is an oral inhibitor of ribonucleotide reductase (RNR) being evaluated in a Phase 1/2 clinical trial in colorectal cancer patients with BRAFV600E or KRASG12C mutations and resistance gene amplifications. Actual results may difference from those set forth in this press release due to the risks and uncertainties inherent in the business, including, without limitation: the potential for its programs and prospects to be negatively impacted by developments relating to competitors, including the results of studies or regulatory decisions relating to competitors; regulatory developments in the United States and foreign countries; efforts to streamline operations may not produce the efficiencies expected; may use capital resources later than expect; and other risks described in its business.お知らせ • Apr 11Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene AmplificationsBoundless Bio announced that the first patient has been dosed with BBI-825 in a first-in-human, Phase 1/2 clinical trial for patients with locally advanced or metastatic cancer with resistance gene amplifications (NCT06299761). ecDNA are a key driver of high copy number amplification in cancer, and Boundless has validated multiple drug targets that are essential for ecDNA function in cancer cells. BBI-825, the Company's second ecDNA-directed therapy (ecDTx) to enter clinical trials, is a novel, selective, oral small molecule inhibitor of ribonucleotide reductase (RNR), a rate-limiting enzyme responsible for the de novo synthesis of deoxyribonucleotides, the building blocks of DNA. Boundless has identified an essential role for RNR in ecDNA assembly and repair and in the survival of certain oncogene amplified cancer cells.お知らせ • Mar 29Boundless Bio, Inc. has completed an IPO in the amount of $100 million.Boundless Bio, Inc. has completed an IPO in the amount of $100 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 6,250,000 Price\Range: $16 Discount Per Security: $1.12 Transaction Features: Sponsor Backed OfferingBoard Change • Mar 28High number of new and inexperienced directorsThere are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. 5 experienced directors. No highly experienced directors. Co-Founder & Independent Chairman Jonathan Lim is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.株主還元BOLDUS BiotechsUS 市場7D-3.9%-1.8%-0.3%1Y-11.8%32.7%24.1%株主還元を見る業界別リターン: BOLD過去 1 年間で32.7 % の収益を上げたUS Biotechs業界を下回りました。リターン対市場: BOLDは、過去 1 年間で24.1 % のリターンを上げたUS市場を下回りました。価格変動Is BOLD's price volatile compared to industry and market?BOLD volatilityBOLD Average Weekly Movement10.7%Biotechs Industry Average Movement10.9%Market Average Movement7.2%10% most volatile stocks in US Market16.2%10% least volatile stocks in US Market3.2%安定した株価: BOLD 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: BOLDの 週次ボラティリティ ( 11% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト201828Zach Hornbyboundlessbio.comバウンドレス・バイオ社は、癌遺伝子増幅癌患者を治療するための染色体外DNA（ecDNA）指向性治療薬を開発する臨床段階の癌治療企業である。同社の主要製品候補であるBBI-940は、ecDNA指向性治療薬候補（ecDTx）で、エストロゲン受容体陽性およびヒト上皮成長因子受容体2陰性の乳がん患者、ならびにトリプルネガティブ乳がん腔内アンドロゲン受容体サブタイプ患者を対象に第1/2相臨床試験中である。同社は以前Pretzel Therapeutics, Inc.として知られていたが、2019年7月にBoundless Bio, Inc.に社名を変更した。Boundless Bio, Inc.は2018年に法人化され、カリフォルニア州サンディエゴに本社を置いている。もっと見るBoundless Bio, Inc. 基礎のまとめBoundless Bio の収益と売上を時価総額と比較するとどうか。BOLD 基礎統計学時価総額US$33.40m収益（TTM）-US$55.99m売上高(TTM)n/a0.0xP/Sレシオ-0.6xPER（株価収益率BOLD は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計BOLD 損益計算書（TTM）収益US$0売上原価US$0売上総利益US$0その他の費用US$55.99m収益-US$55.99m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-2.50グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率0%BOLD の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/18 11:15終値2026/05/15 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Boundless Bio, Inc. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関Hiroshi ShibutaniGoldman SachsRichard J. LawGoldman SachsMichael SchmidtGuggenheim Securities, LLC1 その他のアナリストを表示
お知らせ • Apr 30Boundless Bio, Inc., Annual General Meeting, Jun 15, 2026Boundless Bio, Inc., Annual General Meeting, Jun 15, 2026.
お知らせ • Apr 18Boundless Bio Presents Preclinical Data Supporting Ongoing Clinical Development of BBI-940Boundless Bio presented preclinical data supporting its lead ecDNA-directed therapy (ecDTx), BBI-940, at the American Association for Cancer Research Annual Meeting 2026. Boundless has identified a novel kinesin target (“Kinesin”) essential to ecDNA segregation and inheritance in cancer cells, but non-essential in healthy cells. BBI-940, an oral, and selective Kinesin degrader, is currently being evaluated in the Phase 1 KOMODO-1 trial in patients with advanced or metastatic ER+/HER2- breast cancer and TNBC-LAR. Genetic and pharmacologic degradation of Kinesin caused ecDNA mis-segregation, ecDNA depletion, and reduced viability of ecDNA+ cancer cells. Selective degradation of Kinesin in a panel of tumor cell lines demonstrated sensitivity across multiple tumor types and 32% sensitivity in breast cancer cell lines, including those positive for ecDNA and FGFR1 gain. This molecularly defined subgroup for Kinesin degradation was further validated in vivo with demonstrated monotherapy tumor regressions in an ecDNA+ TNBC-LAR model, and significant antitumor activity as monotherapy and combination in an ecDNA+/FGFR1+ ER+ breast cancer model. BBI-940 targets a specific kinesin protein, “Kinesin”, essential for ecDNA segregation and inheritance in cancer cells, but non-essential in healthy cells. BBI-940 is designed to exploit the heightened dependence of ecDNA-positive tumors on mitotic machinery by degrading Kinesin to induce mitotic catastrophe and cell death.
New Risk • Mar 09New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 6.7% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 6.7% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$74m net loss in 3 years). Market cap is less than US$100m (US$25.3m market cap).
Price Target Changed • Feb 11Price target increased by 33% to US$4.00Up from US$3.00, the current price target is provided by 1 analyst. New target price is 260% above last closing price of US$1.11. Stock is down 50% over the past year. The company is forecast to post a net loss per share of US$2.48 next year compared to a net loss per share of US$3.85 last year.
分析記事 • Feb 04Is Boundless Bio (NASDAQ:BOLD) In A Good Position To Invest In Growth?Just because a business does not make any money, does not mean that the stock will go down. For example, although...
お知らせ • Jan 20Boundless Bio, Inc. Advances Novel Kinesin Degrader Program BBI-940Boundless Bio, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for its novel Kinesin oral degrader program, BBI-940. The Company also provided updates on the POTENTIATE clinical trial of BBI-355 and BBI-825 and its capital position. The acceptance of the BBI-940 IND enables Boundless to advance the program into a first-in-human clinical trial for patients with metastatic breast cancer, KOMODO-1 (Kinesin Oral Molecular Degrader for Oncology-1), which is expected to initiate in the first half of 2026. Boundless's novel Kinesin oral de grader program targets a previously undrugged kinesin involved in DNA segregation, including ecDNA segregation, during mitosis. Following a strategic portfolio review, Boundless Bio has elected to cease enrollment of the Phase 1/2 POTENTIATE trial evaluating the combination of BBI-355, its oral, selective CHK1 inhibitor and BBI-825, its oral, selective RNR inhibitor, in oncogene-amplified cancers. This decision reflects market considerations, clinical data, and the Company's prioritization of programs with the greatest potential to deliver meaningful clinical impact and long-term value.
お知らせ • Apr 30Boundless Bio, Inc., Annual General Meeting, Jun 15, 2026Boundless Bio, Inc., Annual General Meeting, Jun 15, 2026.
お知らせ • Apr 18Boundless Bio Presents Preclinical Data Supporting Ongoing Clinical Development of BBI-940Boundless Bio presented preclinical data supporting its lead ecDNA-directed therapy (ecDTx), BBI-940, at the American Association for Cancer Research Annual Meeting 2026. Boundless has identified a novel kinesin target (“Kinesin”) essential to ecDNA segregation and inheritance in cancer cells, but non-essential in healthy cells. BBI-940, an oral, and selective Kinesin degrader, is currently being evaluated in the Phase 1 KOMODO-1 trial in patients with advanced or metastatic ER+/HER2- breast cancer and TNBC-LAR. Genetic and pharmacologic degradation of Kinesin caused ecDNA mis-segregation, ecDNA depletion, and reduced viability of ecDNA+ cancer cells. Selective degradation of Kinesin in a panel of tumor cell lines demonstrated sensitivity across multiple tumor types and 32% sensitivity in breast cancer cell lines, including those positive for ecDNA and FGFR1 gain. This molecularly defined subgroup for Kinesin degradation was further validated in vivo with demonstrated monotherapy tumor regressions in an ecDNA+ TNBC-LAR model, and significant antitumor activity as monotherapy and combination in an ecDNA+/FGFR1+ ER+ breast cancer model. BBI-940 targets a specific kinesin protein, “Kinesin”, essential for ecDNA segregation and inheritance in cancer cells, but non-essential in healthy cells. BBI-940 is designed to exploit the heightened dependence of ecDNA-positive tumors on mitotic machinery by degrading Kinesin to induce mitotic catastrophe and cell death.
New Risk • Mar 09New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 6.7% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 6.7% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$74m net loss in 3 years). Market cap is less than US$100m (US$25.3m market cap).
Price Target Changed • Feb 11Price target increased by 33% to US$4.00Up from US$3.00, the current price target is provided by 1 analyst. New target price is 260% above last closing price of US$1.11. Stock is down 50% over the past year. The company is forecast to post a net loss per share of US$2.48 next year compared to a net loss per share of US$3.85 last year.
分析記事 • Feb 04Is Boundless Bio (NASDAQ:BOLD) In A Good Position To Invest In Growth?Just because a business does not make any money, does not mean that the stock will go down. For example, although...
お知らせ • Jan 20Boundless Bio, Inc. Advances Novel Kinesin Degrader Program BBI-940Boundless Bio, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for its novel Kinesin oral degrader program, BBI-940. The Company also provided updates on the POTENTIATE clinical trial of BBI-355 and BBI-825 and its capital position. The acceptance of the BBI-940 IND enables Boundless to advance the program into a first-in-human clinical trial for patients with metastatic breast cancer, KOMODO-1 (Kinesin Oral Molecular Degrader for Oncology-1), which is expected to initiate in the first half of 2026. Boundless's novel Kinesin oral de grader program targets a previously undrugged kinesin involved in DNA segregation, including ecDNA segregation, during mitosis. Following a strategic portfolio review, Boundless Bio has elected to cease enrollment of the Phase 1/2 POTENTIATE trial evaluating the combination of BBI-355, its oral, selective CHK1 inhibitor and BBI-825, its oral, selective RNR inhibitor, in oncogene-amplified cancers. This decision reflects market considerations, clinical data, and the Company's prioritization of programs with the greatest potential to deliver meaningful clinical impact and long-term value.
分析記事 • Oct 17Here's Why We're Watching Boundless Bio's (NASDAQ:BOLD) Cash Burn SituationEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Price Target Changed • Aug 24Price target decreased by 13% to US$3.50Down from US$4.00, the current price target is an average from 2 analysts. New target price is 199% above last closing price of US$1.17. Stock is down 69% over the past year. The company is forecast to post a net loss per share of US$2.46 next year compared to a net loss per share of US$3.85 last year.
お知らせ • Jun 30+ 16 more updatesBoundless Bio, Inc.(NasdaqGS:BOLD) dropped from Russell 2000 Growth IndexBoundless Bio, Inc.(NasdaqGS:BOLD) dropped from Russell 2000 Growth Index
お知らせ • May 26+ 1 more updateBoundless Bio, Inc. Announces Workforce Reduction of Approximately One-Third of the Company’s WorkforceOn May 23, 2025, Boundless Bio, Inc. announced a workforce reduction of approximately one-third of the Company’s workforce. The Company expects to incur one-time costs of approximately $1.2 million in connection with the workforce reduction primarily related to one-time termination benefits (some of which are contractual), including severance and healthcare related benefits. The Company estimates that the workforce reduction will be substantially completed in the second quarter of 2025 and that the majority of the related charges will be recognized in the Company’s second quarter financial results of operations. The estimate of costs that the Company expects to incur and the timing thereof are subject to a number of assumptions, and actual results may differ materially. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the implementation of the workforce reduction.
お知らせ • Apr 30Boundless Bio, Inc., Annual General Meeting, Jun 23, 2025Boundless Bio, Inc., Annual General Meeting, Jun 23, 2025.
New Risk • Apr 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 18% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$94m net loss in 2 years). Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (US$32.3m market cap).
お知らせ • Feb 03Boundless Bio Appoints Robert Doebele, M.D., Ph.D., as Chief Medical OfficerBoundless Bio, Inc. announced that Robert (“Bob”) Doebele, M.D., Ph.D., has been appointed as Chief Medical Officer. Dr. Doebele was the co-founder of Rain Oncology, Inc., (acquired by Pathos AI), a precision oncology company, where he served as Chief Scientific and Medical Officer, directing the research and development of innovative therapies targeting oncogenic drivers in tumor-agnostic, biomarker-driven trials. Specifically, he led the clinical development plans for milademetan, a small molecule MDM2 inhibitor, Phase 2 planning for tarloxotinib, a hypoxia-activated pan-HER kinase inhibitor, and the development of a preclinical program focused on inducing synthetic lethality by inhibiting RAD52. Dr. Doebele previously led the research and clinical trials at the University of Colorado that launched the TRK inhibitor field by demonstrating that NTRK1/2/3 gene fusions represent a novel tumor agnostic target in cancer, a strategy that ultimately led to the approval of Vitrakvi® (larotrectinib) and Rozlytrek® (entrectinib). He also served as the director of the Thoracic Oncology Research Initiative at the University of Colorado Cancer Center and co-founded and co-directed the University of Colorado Molecular Tumor Board. Dr. Doebele received his M.D. and Ph.D. in Immunology from the University of Pennsylvania School of Medicine and an A.B. in Molecular Biology from Princeton University.
分析記事 • Jan 13Here's Why We're Watching Boundless Bio's (NASDAQ:BOLD) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, although...
お知らせ • Dec 13+ 1 more updateBoundless Bio, Inc. Changes to Management TeamBoundless Bio, Inc. announced that Klaus Wagner, M.D., Ph.D., Chief Medical Officer (CMO), and Neil Abdollahian, Chief Business Officer (CBO), will depart the company at the end of December and in early January 2025, respectively. James L. Freddo, M.D., current advisor to Boundless with nearly 30 years of clinical leadership experience in biopharmaceutical companies, will serve as Interim CMO while the company conducts a search for a permanent hire. Dr. Freddo’s extensive background includes serving as CMO and later as a member of the board of directors at Ignyta, Inc., CMO and Senior Vice President, Development at Anadys Pharmaceuticals, and Vice President, Clinical Development, Oncology at Pfizer. The company does not intend to appoint a new CBO at this time.
お知らせ • Oct 14Boundless Bio Announces Departure of Jami Rubin as Chief Financial OfficerBoundless Bio announced that Jami Rubin has stepped down from her role as Chief Financial Officer (CFO) for personal reasons. Boundless Bio does not plan to hire a successor CFO at this time; David Hinkle, Senior Vice President, Finance and Controller, will maintain responsibility for the company’s Finance operations and assume the roles of principal financial and accounting officer.
分析記事 • Sep 27Will Boundless Bio (NASDAQ:BOLD) Spend Its Cash Wisely?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
お知らせ • Aug 13Boundless Bio Provides Business Updates Focused on Key Value DriversBoundless Bio, Inc. provided business updates for the company's top strategic priorities. In alignment with its strategic priorities, Boundless Bio has narrowed its discovery research work and, as a result, modestly reduced its workforce. BBI-355, a novel, oral, potent, selective CHK1 inhibitor targeting replication stress for cancer patients with driver oncogene amplifications. The company presented preclinical and clinical pharmacodynamic data on BBI-355 at the American Association for Cancer Research (AACR) Annual Meeting in April 2024. Enrollment is progressing in the Phase 1/2 POTENTIATE clinical trial evaluating BBI-355 as a single agent and in combination with targeted therapies in patients with locally advanced or metastatic solid tumors with oncogene amplifications. BBI-825, a novel, oral, powerful RNR inhibitor targeting ecDNA assembly and repair for cancer patients with resistance oncogene amplifications. In April 2024, the company announced the first patient had been dosed with BBI-825 in the Phase 1/2 STARMAP clinical trial. ECTA was previously determined by the FDA to be a non-significant risk device for use as a clinical trial assay (CTA) in the BBI-355 POTENTIATE trial. About BBI-355: BBI-355, is a novel, oral, selective small molecule inhibitor of checkpoint kinase 1 (CHK1) being studied in the ongoing, first-in-human, Phase 1/2 POTentIATE clinical trial (NCT05827614) in cancer patients with oncogene amplifications; BBI-825, is an oral inhibitor of ribonucleotide reductase (RNR) being evaluated in a Phase 1/2 clinical trial in colorectal cancer patients with BRAFV600E or KRASG12C mutations and resistance gene amplifications. Actual results may difference from those set forth in this press release due to the risks and uncertainties inherent in the business, including, without limitation: the potential for its programs and prospects to be negatively impacted by developments relating to competitors, including the results of studies or regulatory decisions relating to competitors; regulatory developments in the United States and foreign countries; efforts to streamline operations may not produce the efficiencies expected; may use capital resources later than expect; and other risks described in its business.
お知らせ • Apr 11Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene AmplificationsBoundless Bio announced that the first patient has been dosed with BBI-825 in a first-in-human, Phase 1/2 clinical trial for patients with locally advanced or metastatic cancer with resistance gene amplifications (NCT06299761). ecDNA are a key driver of high copy number amplification in cancer, and Boundless has validated multiple drug targets that are essential for ecDNA function in cancer cells. BBI-825, the Company's second ecDNA-directed therapy (ecDTx) to enter clinical trials, is a novel, selective, oral small molecule inhibitor of ribonucleotide reductase (RNR), a rate-limiting enzyme responsible for the de novo synthesis of deoxyribonucleotides, the building blocks of DNA. Boundless has identified an essential role for RNR in ecDNA assembly and repair and in the survival of certain oncogene amplified cancer cells.
お知らせ • Mar 29Boundless Bio, Inc. has completed an IPO in the amount of $100 million.Boundless Bio, Inc. has completed an IPO in the amount of $100 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 6,250,000 Price\Range: $16 Discount Per Security: $1.12 Transaction Features: Sponsor Backed Offering
Board Change • Mar 28High number of new and inexperienced directorsThere are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. 5 experienced directors. No highly experienced directors. Co-Founder & Independent Chairman Jonathan Lim is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
